ORBIMED ADVISORS LLC

Q3 2026 13F-HR Holdings

Location
New York, NY
Holdings as of
9/30/2026
Date filed
11/16/2026
Form type
13F-HR
Num holdings
124
Total value ($000)
$5,498,487
Net value change ($000)
+101,707 (1.9%)
New positions
29
Sold out positions
32
Turnover %
38.8%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Snapshot: Change Analysis

Compared to Q2 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
ADARX PHARMACEUTICALS INC 482,663 NEW
BRAVEHEART BIO INC 245,938 NEW
ELECTRA THERAPEUTICS INC 77,458 NEW
TNGX 69,302 NEW
ABBV 67,909 NEW
CDNA 60,762 NEW
ABT 57,223 NEW
TVTX 56,308 391.8%
MRK 52,231 61.3%
BLOSSOMHILL THERAPEUTICS INC 50,594 NEW
Top Reduces (Value $000, Stocks/ETFs)
AZN -109,297 -63.9%
SION -99,441 -88.4%
GPCR -76,958 -64.9%
DYN -71,865 -100.0%
CGON -69,117 -100.0%
QURE -63,659 -76.5%
BSX -63,303 -100.0%
ABVX -54,509 -74.8%
XENE -53,870 -100.0%
BMY -53,299 -100.0%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 45,654 (0.8% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type